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Abstract: Deferiprone is an orally active iron chelator which has emerged from an 
extensive search for new treatment of iron overload. Comparative studies have shown that at 
comparable doses deferiprone may be as effective as deferoxamine in removing body iron. 
Retrospective and prospective studies have shown that deferiprone monotherapy is signiﬁ  cantly 
more effective than deferoxamine in improving myocardial siderosis in thalassemia major. 
Agranulocytosis is the most serious side effect associated with the use of deferiprone, occur-
ring in about 1% of the patients. More common but less serious side effects are gastrointestinal 
symptoms, arthralgia, zinc deﬁ  ciency, and ﬂ  uctuating transaminases levels. Deferiprone can be 
used in combination with desferrioxamine. This regimen of chelation is tolerable and attractive 
for patients unable to comply with standard deferoxamine infusions or with inadequate response 
to deferiprone alone. Combination therapy has been effectively used in the management of 
severe cardiac siderosis.
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Introduction
Deferiprone (DFP, Ferriprox™, Kelfer™, L1, CP20) is one of a series of hydroxy-
pyridinone iron chelators synthesized by Dr. Kontoghiorghes in the early to mid 
1980s in the laboratory of Professor R. Hider at the University of Essex in London 
(Kontoghiorghes 1985). The medicinal chemists in this laboratory were researching 
a molecule that could be taken orally, bind iron in conditions of iron overload, such 
as thalassemia, and excrete it from the body. When screening techniques revealed 
efﬁ  cacy in 59Fe-labeled liver macrophages and leukemic cell lines, they tested this 
chelator in iron-loaded mice, rats, and rabbits and found that it was absorbed into the 
body and did excrete excess iron (Hoffbrand 2005).
The excitement over the discovery of a potentially effective oral iron chelator led 
the investigators to initiate a development program of animal studies that would lead 
them to the most rapid route to a trial in humans. The ﬁ  rst publication of the use of 
DFP in man was published in 1987 (Kontoghiorghes et al 1987).
Iron is essential to survival of virtually all species and there is no physiologic 
excretory pathway for this essential element (Andrews 1999). In conditions of primary 
iron overload (eg, hemochromatosis) or secondary (eg, transfusion-dependant thalas-
semia), accumulation of this potentially toxic element, due to the lack of a formal 
mechanism for iron excretion, results in massive iron accumulation, followed by 
iron-induced morbidity and early death, much of which is attributed to the generation 
of iron-induced free radical damage (Rund and Rachmilewitz 2005).
Prior to the discovery of DFP, the only option for treatment of iron overload was 
deferoxamine (DFO), an iron chelator that is not orally absorbed and thus needed 
to be administered parenterally, typically as an 8- to 12-hour nightly infusion, 5–7 
nights a week (Thalassemia International Federation Guidelines 2000). While the Therapeutics and Clinical Risk Management 2007:3(5) 796
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use of DFO for about 2 decades prior to the introduction of 
DFP decreased morbidity and mortality among those who 
were able to comply with night-long infusions, a consistent 
proportion of patients refused therapy or at least were non-
compliant, limiting the usefulness of this chelator, and a key 
factor in spurring on scientists to ﬁ  nd an effective alternative 
chelator. Thus the introduction of DFP was accompanied by 
much hope among hematologists and thalassemia patients 
alike.
The regulatory approval of FerriproxTM in Europe 
(August 1999) was a key advance in the treatment of iron 
overload. Recently, another oral iron chelator, ICL670, has 
been approved for clinical use and additional compounds 
are in various stages of development (Donovan et al 2005; 
Cappellini et al 2006; Galanello et al 2006a).
Pharmacologic properties
DFP (3-hydroxy-1,2-dimethylpyridin-4-one) is a synthetic 
analogue of mimosine, an iron chelator isolated from the 
legume Mimosa paduca (Clarke and Martell 1992). It has 
2 pKas, one of 3.6 and the other of 9.9 (Hider and Liu 2003). 
DFP has strong iron binding properties, with a pFe3+ of 19.6 
and a pFe2+ of only 5.6, indicating a high degree of relative 
speciﬁ  city for the trivalent form of iron, binding it in a 3:1 
complex (Figure 1). Key pharmacologic properties of the 
compound are shown in Table 1 (Clarke and Martell 1992; 
Tam et al 2003). As a water-soluble compound having a 
partition coefﬁ  cient of 0.11 and with a molecular weight of 
only 139 Da, it would be expected to move freely through 
cell membranes throughout the body.
DFP appears to be rapidly and completely absorbed 
after oral administration, with peak plasma levels typically 
occurring about 1 hour after administration. Food slows the 
rate of absorption and thus reduces the peak concentration 
observed, with a Cmax of about 100 µmol/L in the fasting 
state and about 85 µmol/L when fed (Matsui et al 1991; 
Al-Refaie et al 1995a), but does not have much effect on the 
total amount absorbed.
The drug is rapidly eliminated from the body with a 
half-life of about 2 hours due to hepatic biotransformation, 
with glucuronidation accounting for almost all of the metabo-
lism. About 90% of the drug is excreted in the urine as the 
glucuronide. The t½ in healthy subjects (1.3 hours) may be 
shorter than that in thalassemia subjects (2.3 hours) (Stobie 
et al 1993). Since the clearance (CL/F) did not differ between 
the two subject populations, this indicates a different volume 
of distribution in transfused patients, most likely related to 
large differences in iron stores and the ability of DFP to 
access intracellular iron pools.
Comparative efﬁ  cacy
The purpose of an iron chelator is to minimize the risk of 
iron-induced toxicity. Ideally, this is accomplished by the 
combined mechanisms of inactivating current iron deposits 
and removing excess iron from the body through the urine 
and/or feces. By reducing tissue iron stores to levels that 
can be tolerated by the respective organs, the beneﬁ  ts of a 
targeted transfusion program can be achieved without the 
sequelae of iron overload.
Whereas 1–2 mg of iron is absorbed from the diet in 
healthy subjects, patients with transfusion-dependent thalas-
semia typically have an intake many times that amount. Since 
there is no iron elimination pathway, the iron load accumu-
lates in the body, leading to toxicity in key organs such as the 
liver, endocrine organs, and heart. In transfusion-dependent 
thalassemia, the greatest cause of increased body iron is the 
hemoglobin in transfused blood. Transfusion requirements 
are normally determined on the basis of a patient’s hemo-
globin level, but a rough approximation of the increased iron 
load can be estimated if one assumes that splenectomized 
patients might receive about 120 mL red blood cells (RBC)/
kg each year, and non-splenectomized patients, who tend to 
have greater requirements, of about 160 mL RBC/kg each 
year because of enhanced degradation by overactive spleens 
(Thalassemia International Federation Guidelines 2000). 
Table 1 Deferiprone main pharmacologic properties
Denticity Bidentate
Molecular weight  139 Da
pM for Fe+++  19.6
Cmax (fasting state)  100 µmol/L
Elimination, t ½   2–3 h
Cell penetration  Lipophilic
Charge of chelator-iron complex  neutral
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Figure 1 Deferiprone 3:1 complex with iron and DFP-O-glucuronide.Therapeutics and Clinical Risk Management 2007:3(5) 797
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Since 1 mL of pure RBC contains approximately 1 mg iron, 
the total iron received from transfusions, when averaged 
for a year in a “typical” patient, would be about 120–160 
mg iron/kg divided by 365 days or a total of about 0.3–0.4 
mg/kg iron/day. Thus to maintain a negative iron balance, 
one should normally seek to eliminate 0.3–0.4 mg iron/kg 
body weight per day.
Assessment of efﬁ  cacy of an iron chelator can be deter-
mined by measuring the amount of iron eliminated during 
use of the chelator and comparing that with the amount of 
iron input. However, efﬁ  cacy assessment may be somewhat 
more complicated, because one is concerned not only in 
achieving a negative iron balance, but also in minimizing 
iron-induced organ toxicity. Since some chelators may be 
more effective in removing iron from some tissues/organs 
than others, in part based upon their ability to access these 
sites, organ-speciﬁ  c iron removal is another key factor in the 
assessment of efﬁ  cacy.
Consequently, there are several methods used to track 
changes in body iron concentrations resulting from the 
response to chelation therapy, each with its own unique 
advantages. Iron balance provides explicit information 
on the actual removal of iron from the body, but gives no 
precise information on the concentration of iron within any 
particular tissue, or its change subsequent to chelation. The 
measurement of iron within a given tissue, such as the liver, 
provides information speciﬁ  cally about that tissue, but cannot 
be relied upon for levels of iron loading in other tissues. The 
same applies to circulating levels of ferritin, a storage protein 
for iron. The newest development in assessing chelation 
efﬁ  cacy is measuring cardiac iron loading and heart func-
tion (left ventricular ejection fraction, LVEF) with modern 
MRI techniques (Anderson et al 2001). The response to 
DFP for each of the measures of iron chelator effectiveness 
is addressed below.
Iron balance
Measurement of the amount of iron eliminated in urine 
and feces provides an unequivocal determination of the 
effectiveness of an iron chelator in removing iron from the 
body, because these excreta contain negligible amounts of 
iron (about 1 mg/day), except for desquamation of cells 
(gastrointestinal and menses) (Andrews 1999). Since DFP 
may remove iron either from the liver, via the bile, or the rest 
of the body, via the urine, both excreta need to be measured 
for iron content in the case of this chelator. Iron excretion 
was found to be about 25 mg per day in transfusion-depen-
dent patients, in patients receiving a standard dose of 75 
mg/kg/day (Kontoghiorghes et al 1990; Agarwal et al 1992; 
Collins et al 1994; Al-Refaie et al 1995a). On average, this 
amount of excreted iron is sufﬁ  cient to keep them in net 
negative iron balance, in spite of continued transfusions. 
Agarwal et al measured urinary iron excretion in thalassemia 
patients receiving various doses of DFP, ranging from 25 to 
100 mg/kg/day, and demonstrated an increasing amount of 
total iron excretion as the dose increased (Figure 2) (Agarwal 
et al 1992).
Although Agarwal’s data predicted a dose-response 
effect for iron elimination with DFP, he used different 
patients having different iron input and measured only 
urinary iron excretion, leading to tentative conclusions 
that could be conﬁ  rmed only by systematic studies. The 
techniques used in each of the centers that have carried 
out such studies varied, as did the number of days of urine 
and/or fecal collections (Addis et al 1999). Combined with 
the high level of inherent day-to-day variability in iron 
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Figure 2 Urinary iron excretion in thalassemia patients receiving different doses of deferiprone.Therapeutics and Clinical Risk Management 2007:3(5) 798
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excretion, it became apparent that deﬁ  nitive data on total 
body iron excretion could be achieved only by detailed 
study of patients in a systematic fashion obtained with cu-
mulative daily collection of excreta averaged over several 
days, under highly controlled conditions.
The most thorough approach to iron excretion studies 
has been carried out by Grady et al, who used full iron 
balance studies to measure iron excreted in both urine and 
feces and compared the output to the total iron intake with 
food and blood transfusion. Grady’s DFP and DFO-induced 
iron excretion results are summarized in Figure 3, and dem-
onstrate a dose-response relationship for DFP between 50 
and 100 mg/kg/day and for DFO for 40 and 60 mg/kg/day. 
Grady’s total iron balance studies in iron overloaded thal-
assemia patients revealed that 75 mg/kg/day of DFP was 
comparable to DFO 40 mg/kg/day, and increasing the dose 
to 60 mg/kg/day of DFO or 100 mg/kg/day of DFP would 
increase the proportion of patients achieving negative iron 
balance with these chelators (Grady et al 2001, 2002).
Serum ferritin concentrations
The ferritins are a family of iron storage and detoxiﬁ  cation 
proteins which play a critical role in cellular iron homeosta-
sis in humans, other animals, plants and microbes. Shortly 
after chelation therapy for iron overload became available, 
an immunoassay technique for measuring serum ferritin 
concentrations was introduced as a means estimating body 
iron load (Siimes et al 1974) and following serum ferritin 
concentration has been used ever since then to monitor 
response to chelation therapy in conditions such as thalas-
semia (McLaren et al 1983; Modell and Berdoukas 1984). 
While widely used as an index of total body iron load, it 
has the disadvantage that it is also an acute phase reac-
tant and thus spurious values can occur in the presence of 
an inflammatory process, particularly hepatitis, and 
neoplasia (Siimes et al 1974). Although single values can be 
misleading, serum ferritin concentrations can be used long 
term to compare monthly or quarterly changes, providing 
evidence of the success of chelation therapy based on the 
trends in response over time.
Understanding the utility and limitations of serum ferritin 
concentrations, enables one to assess patient response to 
DFP in thalassemia and other conditions. Table 2 sum-
marizes the results of several publications which examined 
the effectiveness of various doses of DFP in lowering iron 
overload in thalassemia patients throughout the world. The 
data reveal that DFP is effective at decreasing or stabiliz-
ing serum ferritin concentrations during continued blood 
transfusions. In general, those patients who had high serum 
ferritin concentrations before starting DFP, experienced the 
greatest decline, whereas those who were well-treated prior 
to starting to DFP, generally experienced a stabilization of 
values, indicative of control of iron load (Cohen et al 2000). 
When using serum ferritin concentrations as a measure of 
iron overload, response to DFP therapy can be monitored and 
doses can be tailored to the needs of the patient to maintain 
concentrations below those associated with iron-induced 
heart disease.
Liver iron concentrations (LIC)
The liver is the organ most suited to accommodate excess 
stores of iron because of its histological composition, size 
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Figure 3 Total iron excretion with different doses of deferoxamine or deferiprone. Red bars indicate mean values. Grey area represents the total iron excretion needed to 
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and anatomical location. Even though the liver is relatively 
well-designed to tolerate high concentrations of iron due to 
lysosomal storage mechanisms and other factors, high levels 
of iron over prolonged periods do induce hepatic ﬁ  brosis and 
even cirrhosis (Prati et al 2004). Early studies revealed that 
LIC increased linearly with the number of units of transfused 
blood (Cazzola et al 1983). Upon initiating chelation therapy, 
the transfusion regimen as well as the dose of chelating agent 
used become the major determinants of LIC and the key 
is to adjust the dose to the needs of the patient, depending 
largely on the patient’s transfusion regimen and efﬁ  cacy of 
the chelator in that individual.
Until recently, most hepatic iron concentrations were 
measured by hepatic biopsy, an invasive procedure that 
patients are not eager to have repeated. Consequently, the 
data evaluating sequential assessments of liver iron concen-
tration over time is sparse. The introduction of a supercon-
ducting quantum interference device (SQUID) was promoted 
for a period of time, but the scarcity of these expensive instru-
ments, together with a lack of validation, minimized their 
use (Fischer et al 2005). More recently, MRI has been used 
to assess hepatic iron concentrations (Anderson et al 2001; 
St Pierre and Clark 2005). It has been clearly established that 
liver iron correlates linearly with the total iron body while 
there is little evidence for the value of liver iron concentra-
tions as a predictor of cardiac iron load or of iron induced 
cardiac disease in patients undergoing chelation treatment 
(Angelucci et al 2000; Anderson et al 2001; Wood et al 2004). 
Although LIC may not have good predictive value for cardiac 
disease-free survival, hepatocellular damage is related to the 
level of hepatic iron loading (Jensen et al 2003). To minimize 
the risk of iron-induced liver damage as well as to reduce total 
body iron stores, a chelator needs to be capable of reducing 
LIC, or maintaining acceptable levels if they have already 
been reduced (Jensen et al 2003).
As is the case for DFO, little information is available 
to assess the effect of DFP on LIC following serial hepatic 
concentrations over time (Hoffbrand et al 2003).
Maggio et al compared the efﬁ  cacy of DFP versus DFO 
in a large multicenter randomized clinical trial (Maggio et al 
2002). They found no difference in the reduction of liver iron 
content measured by MRI or liver biopsy between the two 
groups. Another randomized controlled study designed to 
compare the abilities of DFP and DFO to remove excess iron 
from the heart, used MRI to assess hepatic iron concentra-
tions. In 61 randomized patients (32 on DFO), a mean dose 
of 92 mg/kg/day of DFP reduced hepatic iron concentrations 
by 0.93 mg/g dry weight vs 1.54 mg/g dry weight in patients 
receiving a mean of 43 mg/kg/day DFO 5.7 days/week 
(p = 0.40) (Pennell et al 2006).
Cardiac magnetic resonance imaging
Magnetic resonance imaging, particularly employing the 
recent MRI T2* methodology, is the most recent parameter 
to be employed in the assessment of iron overload to evalu-
ate cardiac iron load and predict the risk of iron-induced 
cardiac damage. MRI was ﬁ  rst used more than a decade ago 
to estimate, semi-quantitatively, cardiac iron levels in patients 
with iron overload (Olivieri et al 1992). Newer instrumenta-
tion and sophisticated software have greatly improved its 
capability, and it has now been validated against physical 
measurements of iron in liver biopsy samples, as well as 
showing reproducibility in multiple sites with different 
scanners (Westwood et al 2003; Anderson et al 2001). Data 
generated over the last 5 years have shown that MRI T2* 
values have good reproducibility for the measurement of 
Table 2 Changes in serum ferritin levels in thalassemia major patients treated with deferiprone
Study  Number of enrolled  Dose  Length of study   Mean serum ferritin (µg/L)
 patients  (mg/kg/d)  (months)  First  Last
Al-Refaie et al 1992  11  185–119  6–12  5549  4126
Kersten et al 1996  36  50–100  1 to 36  3563  2560
Mazza et al 1998  29  70  >12  3748  2550
Olivieri et al 1998  18  75  55.2  4455  2831
Hoffbrand et al 1998  26  75  4 to 49  2937  2323
Maggio et al 2002  71  75  12  2283  2061
Rombos et al 2000  11  75–100  12  4732  3849
Peng et al 2003  11  75  36  4652  2792
Lucas et al 2002  54  75  9  5743  3558
Taher et al 2004  12  75  60  4302  2229
Cohen et al 2000  187  75  12  2696  2633
Cohen et al 2003   84  75  48  2696  2889Therapeutics and Clinical Risk Management 2007:3(5) 800
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iron concentration, with a CV of approximately 5% (Tanner 
et al 2006a). A quantitative assessment of the magnitude of 
cardiac iron loading in transfusion-dependent thalassemia 
major patients has only recently been published, revealing 
that two thirds of 167 patients in Sardinia maintained on 
DFO therapy exhibited cardiac siderosis (T2* <20 ms) 
(Tanner et al 2006b). Simultaneous assessment of the iron 
content in heart and liver has shown that patients may have 
high concentrations of iron in the liver but low concentra-
tions of iron in the heart, or vice versa (Anderson et al 
2001; Wood et al 2004). Together, these ﬁ  ndings point to 
the critical need to monitor cardiac iron load during chela-
tion therapy to avoid false security regarding the apparent 
efﬁ  cacy of chelation.
DFP and heart
Iron-induced heart failure and arrhythmias are the most 
common causes of death in patients with thalassemia ma-
jor, accounting for about 70% of deaths (Borgna-Pignatti 
et al 2004). Several studies have shown that DFP is more 
effective than DFO in removing cardiac iron. Anderson et al 
(2002) retrospectively compared myocardial iron content, 
using magnetic resonance T2* and cardiac function in 15 
patients receiving long-term DFP with 30 matched thalas-
semia major controls on long-term DFO. The DFP groups 
had signiﬁ  cantly reduced myocardial iron (median 34 
msec vs 11.4 msec; p = 0.02) and higher ejection fraction 
(mean 70.0% ± 6.5% vs 63% ± 6.9%; p = 0.004) than the 
DFO group. The cardiac beneﬁ  t of chelation therapy with 
DFP has been observed in another retrospective study with 
more than 4 years of follow-up (Piga et al 2003). Cardiac 
dysfunction was newly diagnosed in 4% of the DFP treated 
patients and in 20% of the DFO-treated patients (p = 0.007). 
Several prospective trials have compared the myocardial ef-
fects of DFP and DFO (Maggio et al 2002; Peng et al 2003; 
Galia et al 2003; Pennell et al 2006). In two studies DFP 
at 75 mg/kg/day was as effective as DFO, at 50 mg/kg/day 
5–6 days per week, at reducing cardiac iron by magnetic 
resonance signal intensity ratio (SIR) (Maggio et al 2002; 
Galia et al 2003).
Peng et al (2003) prospectively compared cardiac iron, 
estimated by magnetic resonance signal intensity, and LVEF 
over 3 years in 13 patients allocated to DFO (50 mg/kg/
day at least 5 days per week) with 11 patients taking DFP 
(75 mg/kg/day). Cardiac iron was markedly improved in 5 
patients on DFP and only in 2 of the patients on DFO treat-
ment. Mean LVEF improved in the patients taking DFP (from 
58.6 ± 6.8 to 65.2% ± 7.1%), whereas there was no signiﬁ  cant 
change in the DFO group (from 63.3 ± 6.3 to 64.6% ± 7.0%). 
The above-reported results have been recently conﬁ  rmed by 
a larger, prospective controlled trial, where 61 patients previ-
ously treated with DFO were randomized to be maintained 
on DFO (43 mg/kg for 5–7 days per week) or switched to 
DFP (92 mg/kg/d 7 days per week) (Pennell et al 2006). After 
1 year of treatment there was signiﬁ  cantly greater improve-
ment in myocardial T2* for patients taking DFP than those 
on DFO (27% vs 13%; p = 0.023) (Figure 4). Ventricular 
ejection fraction also increased signiﬁ  cantly more in the DFP 
group (3.1% vs 0.3%; p = 0.0034).
The available data show that DFP may have greater 
cardiac beneﬁ  t than DFO. The apparent greater efﬁ  cacy 
of DFP in removing excess cardiac iron may be related to 
the higher ability to enter myocardial cells due to its lower 
molecular weight, neutral charge, and lipophilicity.
DFP safety proﬁ  le
Safety is an issue of major concern for a drug that patients take 
long term. Several factors are responsible for side effects of an 
iron chelator, including route of administration, iron removal 
from iron-dependent enzymes, removal of other divalent cat-
ions such as zinc and calcium, body iron redistribution, and 
direct toxicity to tissue and organs. The safety of DFP has been 
extensively evaluated over the last 15 years and many studies 
have provided a detailed safety proﬁ  le of its long-term use.
Transient gastrointestinal symptoms (GI) such as nau-
sea, vomiting, and abdominal pain, are the most frequently 
reported DFP-related adverse drug reactions (ADR). In a 
long-term prospective study, which monitored 187 patients 
with thalassemia major, most of them followed for 4 years 
for a total drug exposure of 531 patient-years, GI symptoms 
occurred overall in 33% of patients in the ﬁ  rst year (Cohen 
et al 2003). Those events were mild to moderate in intensity 
and resolved without discontinuation of therapy in most 
patients. The 33% decreased to 3% in subsequent years. 
Despite the high frequency, only a restricted number of 
patients (3) withdrew because of GI symptoms. Similar 
results have been reported in other studies (Al-Refaie 1995b; 
Ceci et al 2002; Maggio et al 2002).
Joint symptoms (pain and/or swelling) are the second 
most frequent ADR reported in 3.9%–20% of patients 
taking DFP (Al-Refaie 1995b; Olivieri et al 1995; Ceci et al 
2002; Cohen et al 2003). There seems to be a particular high 
incidence of arthropathy in Indian patients treated with DFP 
(up to 41%), which has been attributed to their severe iron 
overload or undeﬁ  ned ethnic genetic background (Choudry 
et al 2004). Joint symptoms, sometimes associated with Therapeutics and Clinical Risk Management 2007:3(5) 801
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myalgia, are mild/moderate in most patients, but occasionally 
may be severe enough to warrant interruption of the drug, re-
duction of the dose, or discontinuation. Overall about 2% of the 
patients discontinued DFP because of joint symptoms. Unlike 
GI problems, which usually manifest in the ﬁ  rst weeks of treat-
ment, joint problems may occur even after years of treatment. 
Sequential assessments of antinuclear antibody, rheumatoid 
factor, anti-double stranded DNA, and anti-histone antibodies 
indicate that the episodes of arthropathy are not associated 
with an autoimmune disease (Cohen et al 2000).
Overall fluctuating serum alanine aminotransferase 
(ALT) have been reported in about 7% of the patients par-
ticularly in the ﬁ  rst months of treatment. The transient nature 
of the changes in ALT levels and the absence of a progres-
sive increase over time has been reported in several studies 
(Al-Refaie et al 1995b; Olivieri et al 1995; Maggio et al 2002; 
Cohen et al 2003). However, careful monitoring of ALT 
levels at regular intervals is recommended and DFP interrup-
tion or dose reduction should be considered for patients with 
substantial and persistent increase of transaminases.
In 1998 one report suggested that DFP use was associ-
ated with an increase in liver ﬁ  brosis in 5 out 14 patients 
(Olivieri et al 1998). An accompanying editorial outlined 
that the design of the study, the small liver biopsy samples, 
and the lack of an appropriate control group precluded any 
deﬁ  nitive conclusion (Kowdley and Kaplan 1998). A separate 
review of the same 14 biopsies did not conﬁ  rm the original 
results (Callea 1998). Since then, several studies conducted 
to evaluate liver histology changes during therapy with DFP 
showed no evidence of DFP-induced liver ﬁ  brosis (Hoffbrand 
et al 1998; Piga et al 1998; Galanello 1999). The analysis by 
3 independent pathologists of the largest collection of liver 
biopsies from patients treated with DFP for a mean of 3.1 
years demonstrated the lack of progressive hepatic ﬁ  brosis 
during long term therapy with DFP (Wanless et al 2002).
Low plasma zinc levels have been reported in patients 
treated with DFP, particularly in those with diabetes mellitus. 
In a long-term controlled study a slight decrease in plasma 
zinc was observed over time, but the mean value remained 
within the normal reference range (Taher et al 2002; Cohen 
Figure 4 Change in myocardial T2* at 6 and 12 months in patients taking deferiprone or deferoxamine. Reproduced with permission from Pennell DJ, Berdoukas V, 
Karagiorga M, et al 2006. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood, 
107:3738–44. Copyright © 2006. The American Society of Hematology.Therapeutics and Clinical Risk Management 2007:3(5) 802
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et al 2003). Overall low plasma zinc levels are not a common 
problem in patients treated with DFP, but periodic monitoring 
can be suggested especially in patients with diabetes.
Reddish discoloration of urine due to excretion of the iron-de-
feriprone complex has been reported in DFP-treated patients.
Studies in non-iron loaded animals have shown that DFP is 
embryotoxic and teratogenic (Berdoukas et al 1993). Although 
few uneventful pregnancies with healthy newborns have been 
reported, women of child bearing age should be counseled to 
avoid pregnancy while on therapy with DFP (Goudsmit and 
Jaeger et al 1992; Kersten 1992; Gogtay and Agarwal 2002). 
DFP should be also avoided in breast feeding mothers.
Agranulocytosis, deﬁ  ned as a conﬁ  rmed absolute neutro-
phil count (ANC) less than 0.5 × 109/L, is considered the most 
serious adverse effect of DFP. In a prospective, long-term 
study including 187 patients followed for 4 years, speciﬁ  cally 
designed to determine the incidence of severe adverse events, 
agranulocytosis occurred in 0.5% of the patients (0.2 episodes 
per 100 patient-years) (Cohen et al 2003). Similar results have 
been reported in a large Italian study including 532 patients 
(1% of the patients, 0.3 episodes per 100 patient-years) (Ceci 
et al 2002). Agranulocytosis usually resolves with interruption 
of DFP, but sometimes for faster recovery treatment with G-CSF 
is needed. Fatal outcome due to severe infections associated with 
DFP-related agranulocytosis has been reported in some patients 
(Apotex Research Inc. 2003; Muller et al 2000).
Milder episodes of neutropenia, deﬁ  ned as an ANC be-
tween 0.5 and 1.5 × 109/L, have been reported in 3.6%–8.5% 
of the patients (Al-Refaie et al 1995b; Ceci et al 2002; 
Cohen et al 2003). Milder neutropenia is usually reversible 
on discontinuation of the drug. The reason for the reduced 
neutrophil count during DFP treatment is uncertain. Agranulo-
cytosis is not dose-dependent. It seems to be an idiosyncratic 
response and although it is more frequent in the ﬁ  rst year of 
treatment, it has been reported up to 4 years from starting 
DFP therapy. It appears that the mechanism for agranulocy-
tosis and milder neutropenia may be different. Neutropenia 
occurs significantly more often in non-splenectomized 
patients and in association with viral infections (Cohen et al 
2000). Because of risk of recurrence, reintroduction of DFP 
after an initial episode of agranulocytosis is not recommended. 
It should be emphasized that careful monitoring of blood 
counts remains a critical component of therapy with DFP.
Association of deferiprone with 
deferoxamine
The availability of two chelators (DFO and DFP), besides 
monotherapy with one of them, makes possible two chelation 
strategies: alternate chelation and combined chelation. Alternate 
therapy means that in each single day only one of the two chela-
tors is taken by the patient, while combination therapy indicates 
that the two chelators are taken in the same day.
Alternate therapy
Alternate therapy is very common in clinical practice prob-
ably because by introducing oral DFP and reducing the 
weekly number of DFO infusions, it may be a practical 
approach to improve compliance with iron chelation for 
patients poorly compliant with DFO monotherapy. The 
effectiveness of alternating treatment was initially reported 
by Aydinok et al (1999) in a small non-controlled study. 
A prospective, randomized, controlled trial on the safety 
and efﬁ  cacy of alternating DFO and DFP has been recently 
reported (Galanello et al 2006b). In this study 60 patients 
with thalassemia major regularly transfused, were random-
ized either to continue the standard therapy with DFO at 
30–40 mg/kg/day for 5–7 days per week, or to receive an 
alternating regimen of DFP 75 mg/kg body weight, divided 
into 3 doses 5 days a week and DFO (30–40 mg/kg/day) the 
other 2 days of the week. After 1 year of treatment both arms 
resulted in equivalent decreases of serum ferritin (–248 ± 791 
µg/L for the alternating regimen vs –349 ± 573 µg/L for the 
DFO monotherapy group; p = 0.58) and liver iron concentra-
tion determined by SQUID (–65 ± 615 vs –239 ± 474 µgFe/g 
liver; p = 0.22). Overall the alternating use of both chelators 
was not associated with increased toxicity and no signiﬁ  cant 
difference was observed in the proportion of patients with 
adverse events in the two therapy groups, although the nature 
of the adverse events differed according to the chelation regi-
men: DFO was associated with local reactions at the site of 
infusion, DFP with GI symptoms.
Combined therapy
Combined use of DFO and DFP was introduced into the 
clinical practice by Wonke et al (1998) in a small group 
of patients. Combined chelation offers several potential 
advantages. Drugs with distinct physicochemical properties 
have different iron-carrying capacities and may access dif-
ferent iron pools. Combined therapy may achieve levels of 
iron excretion that cannot be achieved by either drug alone 
without loss of compliance and without increased toxic-
ity (Hoffbrand et al 2003). This approach is attractive for 
patients unable to comply with standard DFO infusions (5–7 
per week) or with inadequate response to DFP alone. Several 
non-controlled studies using different doses of chelators, dif-
ferent regimens (number of days per week on DFO and DFP), Therapeutics and Clinical Risk Management 2007:3(5) 803
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for variable periods have been reported (Wonke et al 1998; 
Balveer et al 2001; Alymara et al 2002; Farmaki et al 2002; 
Kattamis et al 2002; Mourad et al 2003; Origa et al 2005). In 
most of these studies serum ferritin signiﬁ  cantly decreased 
compared with initial levels and a higher urinary iron excre-
tion was observed. Some of these studies evaluated the clini-
cal efﬁ  cacy of the combination therapy. Origa et al (2005) 
reported a signiﬁ  cant improvement in LVEF from 48.6% ± 
9% at baseline to 57.0% ± 6% (p < 0.0001) without modify-
ing cardiac therapy. The effect of combination therapy on 
glucose metabolism has been described by Farmaki et al 
(2006). Glucose responses were improved at all times during 
an oral glucose tolerance test, particularly in patients in early 
stages of glucose intolerance.
The effect of combined therapy versus DFO monotherapy 
on myocardial iron overload was evaluated in a prospective 
randomized placebo controlled trial using cardiovascular 
magnetic resonance (Tanner et al 2007). Sixty-ﬁ  ve patients 
with mild to moderate cardiac iron loading (heart T2* 8–20 
msec) were randomized to receive either DFO and placebo or 
DFO and DFP. There were signiﬁ  cant improvements in the 
combined treatment group compared with the placebo group 
in myocardial T2* (ratio of change in geometric means 1.50 
vs 1.24; p = 0.02) and LVEF (2.6% vs 0.6%; p = 0.05).
The role of combination therapy in the management of 
severe cardiac siderosis has been speciﬁ  cally addressed in 
some case report and in prospective studies (Wu et al 2004; 
Tsironi et al 2005; Tavecchia et al 2006; Porcu et al 2007). 
Patients with severe end stage heart failure had a dramatic 
improvement in symptoms and myocardial function after 
initiation of treatment with combination of DFP and DFO. 
A prospective study, including 15 patients with severe myo-
cardial siderosis (heart T2*< 8 msec) and reduced LVEF, has 
shown that combined chelation provides an effective means 
of reducing myocardial iron and improving cardiac function. 
In this study myocardial T2* increased from 5.7 ± 0.98 at 
baseline to 7.1 ± 1.96 after 6 months of combined chela-
tion and LVEF improved signiﬁ  cantly (Tanner M, personal 
communication).
Based on the above studies and on data showing that DFP 
may have a greater effect in removing cardiac iron than DFO 
(see below) combination therapy should be considered as an 
alternative to continuous intravenous DFO monotherapy.
Careful metabolic iron balance studies assessing the total 
(urinary and fecal) iron excretion have shown an additive 
effect when DFO and DFP were given sequentially and a 
synergistic effect, in some patients, when the drugs were 
given simultaneously (Grady et al 2002). The hypothesis to 
explain the synergy is that the small DFP molecule acts as a 
shuttle mobilizing iron from intracellular compartments to the 
bloodstream, where DFP may exchange iron with the larger 
DFO molecule which has a higher afﬁ  nity for iron.
Over the past 6 years numerous clinical studies have 
provided data on the safety of the association of DFP with 
DFO (Alymara et al 2002; Farmaki et al 2002; Kattamis et al 
2002; Origa et al 2005). Combination regimens have shown 
no unanticipated adverse drug reactions.
Deferiprone and survival
The published data showing superior efﬁ  cacy of DFP in the 
management of cardiac siderosis and cardiac disease have 
received support from outcome studies looking at patient’s 
survival. A retrospective 5-year observational study compar-
ing a group of 54 DFP-treated patients with 75 DFO-treated 
patients indicated that cardiac-disease-free survival was 
signiﬁ  cantly better in the DFP group (p = 0.0003) (Piga 
et al 2003). A recent multicenter study involving 359 patients 
receiving DFO and 157 patients switched to DFP showed that 
during the 9-year observation period there was a total of 52 
cardiac events, including 15 cardiac deaths, all occurring in 
the patients treated with DFO (Borgna-Pignatti et al 2006). 
Overall 14.5% of the DFO patients developed a cardiac event 
vs 0% of the DFP patients. Telfer et al (2006) analyzed the 
survival trends in Cypriot patients with thalassemia major 
born after 1974 and found signiﬁ  cant decline of cardiac 
deaths and a marked improvement in survival since 2000, 
probably due to the introduction of combination therapy.
Conclusion
The available data appear to demonstrate that DFP is an ef-
fective oral iron chelator able to reduce iron overload and to 
maintain a safe body iron level. Moreover, deferiprone alone or 
in combination with DFO seems to be superior to DFO mono-
therapy in improving myocardial siderosis and cardiac func-
tion. The safety of DFP has been extensively evaluated over 
the last 10 years. The relatively large number of patients and 
the extended period of intensive follow-up provide a detailed 
long-term safety proﬁ  le. In general, adverse drug reactions 
with DFP are predictable and the risk manageable provided a 
continuous and careful monitoring of the patients.
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